Stryker Corporation (NYSE: SYK) and Trivascular Technologies (NASDAQ:TRIV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitabiliy, risk, earnings, institutional ownership, analyst recommendations and dividends.

Earnings & Valuation

This table compares Stryker Corporation and Trivascular Technologies’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Stryker Corporation $11.79 billion 4.47 $3.23 billion $4.45 31.71
Trivascular Technologies N/A N/A N/A N/A N/A

Stryker Corporation has higher revenue and earnings than Trivascular Technologies.


This table compares Stryker Corporation and Trivascular Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Stryker Corporation 14.33% 24.26% 11.20%
Trivascular Technologies -143.61% -766.90% -66.97%

Analyst Recommendations

This is a summary of recent ratings and target prices for Stryker Corporation and Trivascular Technologies, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stryker Corporation 3 6 11 0 2.40
Trivascular Technologies 0 0 0 0 N/A

Stryker Corporation presently has a consensus price target of $135.36, indicating a potential downside of 4.08%. Given Stryker Corporation’s higher possible upside, analysts clearly believe Stryker Corporation is more favorable than Trivascular Technologies.

Insider and Institutional Ownership

74.3% of Stryker Corporation shares are owned by institutional investors. 7.4% of Stryker Corporation shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


Stryker Corporation pays an annual dividend of $1.70 per share and has a dividend yield of 1.2%. Trivascular Technologies does not pay a dividend. Stryker Corporation pays out 38.2% of its earnings in the form of a dividend. Trivascular Technologies has raised its dividend for 6 consecutive years.


Stryker Corporation beats Trivascular Technologies on 9 of the 11 factors compared between the two stocks.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.

About Trivascular Technologies

Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with's FREE daily email newsletter.